MTE #25: Next Generation Multidisciplinary Liver Tumor Boards for Hepatobiliary Malignancies (Ticketed)

Multidiciplinary tumor boards (MDTBs) are pivotal for liver cancer treatment, especially given the significant transformation in the hepatocellular carcinoma (HCC) treatment paradigm in recent years. Perons with HCC are often faced with competing mortalities—advanced liver disease and advanced cancer—neccessitating treatment options grounded in preserving liver function and quality of life. Connect with topic experts to discuss the evolution and restructuring of MDTBs in the context of hepatobiliary malignancies. Faculty review data demonstrating that MDTBs enhance evidence-based practices, guideline implementation, and the likelihood of curative options while preserving quality of life. Presenters discuss the need for MDTBs to adapt as the treatment landscape for primary liver cancer grows increasingly intricate, propelled by an expanding array of systemic and locoregional therapies and advancements in molecular biology. Speakers highlight the necessity of reimagining MDTB structures to seamlessly integrate cutting-edge technologies, including artificial intelligence, molecular biology, digital pathology, and advanced imaging. Faculty also address the optimal composition of the next generation of MDTBs, and how the establishment these boards holds the promise of advancing precision medicine, catalyzing research, and driving clinical trials to address unmet needs while redefining the multidisciplinary care paradigm for liver cancers. Speakers review real-world cases to highlight various treatment strategies in persons presenting with different stages of liver cancer.